Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nature Immunology

• Publication date

  2003-10-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ni988PMID 14556006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?

  2004cited by this paper
• Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

  2003cited by this paper
• The TIM gene family: emerging roles in immunity and disease

  2003cited by this paper
• Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

  2003cited by this paper
• Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

  2002cited by this paper
• Neutralization of Hepatitis A Virus (HAV) by an Immunoadhesin Containing the Cysteine-Rich Region of HAV Cellular Receptor-1

  2001cited by this paper
• Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family

  2001cited by this paper
• CTLA-4 regulates induction of anergy in vivo.

  2001cited by this paper
• Distinct cellular receptor interactions in poliovirus and rhinoviruses

  2000cited by this paper
• Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells1

  2000cited by this paper
• Cutting Edge: Chandra, a Novel Four-Transmembrane Domain Protein Differentially Expressed in Helper Type 1 Lymphocytes

  2000cited by this paper
• Cutting Edge: IL-4 Induces Functional Cell-Surface Expression of CXCR4 on Human T Cells

  1998cited by this paper
• CCR5 is characteristic of Th1 lymphocytes

  1998cited by this paper
• Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes

  1998cited by this paper
• Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s

  1998cited by this paper
• The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells.

  1998cited by this paper
• Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels.

  1998cited by this paper
• The Cys-Rich Region of Hepatitis A Virus Cellular Receptor 1 Is Required for Binding of Hepatitis A Virus and Protective Monoclonal Antibody 190/4

  1998cited by this paper
• T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function.

  1998cited by this paper
• IL-4 induces functional cell-surface expression of CXCR4 on human T cells.

  1998cited by this paper
• Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

  1997cited by this paper
• A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

  1997cited by this paper
• Functional diversity of helper T lymphocytes

  1996cited by this paper
• The expanding universe of T-cell subsets: Th1, Th2 and more.

  1996cited by this paper
• Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus.

  1996cited by this paper
• Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.

  1995cited by this paper
• An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.

  1995cited by this paper
• Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation.

  1995cited by this paper
• B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

  1995cited by this paper
• Nebulized but not parenteral IFN-gamma decreases IgE production and normalizes airways function in a murine model of allergen sensitization.

  1994cited by this paper
• In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen

  1993cited by this paper
• MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1

  1993cited by this paper
• Regulation of immunity to parasites by T cells and T cell-derived cytokines.

  1992cited by this paper
• Why are proteins O-glycosylated?

  1990cited by this paper
• Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

  1986cited by this paper
• The molecular basis of the requirement for antigen processing of pigeon cytochrome c prior to T cell activation.

  1985cited by this paper
• Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C.

  1983cited by this paper

• IMMUNOLOGICAL ASPECTS OF CROHN’S DISEASE: A REGULATORY FUNCTION OF TIM-3/ GALECTIN-9 IN LYTH1

  2026cites this paper
• Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

  2026cites this paper
• Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance

  2026cites this paper
• The role of immune checkpoint molecules in cancers

  2026cites this paper
• Galectins as Drivers of Host-Pathogen Dynamics in Mycobacterium tuberculosis Infection.

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors

  2025cites this paper
• Breaking the Triad: Immune Tolerance Induction Without Antigen Co-Presentation via Tim Agonist for the Treatment of Autoimmune Diseases

  2025cites this paper
• A novel loss of function mutation in the HAVCR2 gene in a patient diagnosed with Hodgkin’s lymphoma

  2025cites this paper
• Identification of natural killer cell-characteristic genes in atherosclerosis based on bioinformatics analysis

  2025cites this paper
• The significant impact of T-cell immunoglobulin and mucin domain 3(Tim-3) gene polymorphism on HCV infection and viral load.

  2025cites this paper
• Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors

  2025cites this paper
• Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy

  2025cites this paper
• Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

  2025cites this paper
• LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

  2025cites this paper
• Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer

  2025cites this paper
• Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding

  2025cites this paper
• Novel insights into the effect of sTIM-3 on NLRP3 inflammasome via interacting with ASC

  2025cites this paper
• Immune checkpoint TIM-3 in tumor immunotherapy

  2025influential citation
• THERAPEUTIC POTENTIAL OF TIM-3 INHIBITION IN CANCER, VIRAL INFECTIONS, AND AUTOIMMUNE DISORDERS.

  2025cites this paper
• Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future

  2025cites this paper
• Regulatory T Cells in Colon Cancer: Implications for Pathogenesis, Prognosis and Emerging Therapeutic Strategies

  2025cites this paper
• Dichotomous effects of Galectin-9 in disease modulation in murine models of inflammatory bowel disease

  2025cites this paper
• Soluble form of immune checkpoints in autoimmune diseases.

  2024cites this paper
• Immune responsiveness in stable kidney transplantation patients: Complete inhibition of T‐cell proliferation but residual T‐cell activity during maintenance immunosuppressive treatment

  2024cites this paper
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• Inborn Errors of Immunity and Cytokine Storm Syndromes.

  2024cites this paper
• TIM‐3 Expression in Endometriosis

  2024cites this paper
• Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression

  2024cites this paper
• Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

  2024cites this paper
• The role of extracellular vesicle immune checkpoints in cancer.

  2024cites this paper
• Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy

  2024cites this paper
• LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

  2024cites this paper
• An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population

  2024cites this paper
• Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy

  2024cites this paper
• Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

  2024cites this paper
• Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

  2024cites this paper
• The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy

  2024cites this paper
• The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.

  2024cites this paper
• Insight of immune checkpoint inhibitor related myocarditis.

  2024cites this paper
• Novel Peptide-Based 68Ga-Labeled Radiotracer for Preclinical Studies of TIM3 Expression.

  2024cites this paper
• Discovery of TIM-3: Beyond a Th1 Regulator.

  2024cites this paper
• Management of In-transit Disease: Regional Therapies, Intralesional Therapies, and Systemic Therapy.

  2024cites this paper
• Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrows of adult acute myeloid leukemia patients.

  2024cites this paper
• TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3

  2024cites this paper
• Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

  2024cites this paper
• Participation of T cells in generating immune protection against cancers.

  2024cites this paper
• Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation

  2024cites this paper
• The evaluation of PD-1 and Tim-3 expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss.

  2024cites this paper
• Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma

  2024cites this paper
• Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance

  2024cites this paper
• T-cell immunotherapy for melanoma.

  2024cites this paper
• Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy

  2023cites this paper
• Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis

  2023cites this paper
• Galectin-9 contributes to the survival of fully allogeneic skin grafts by modulating effector T cells and Tregs imbalance.

  2023cites this paper
• Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease

  2023cites this paper
• Immune checkpoint inhibitors and reproductive failures.

  2023cites this paper
• Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children

  2023cites this paper
• Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

  2023cites this paper
• Tim-3 blockade enhances the clearance of Chlamydia psittaci in the lung by promoting a cell-mediated immune response.

  2023cites this paper
• Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview

  2023cites this paper
• Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus

  2023cites this paper
• Tim-3 Is Differentially Expressed during Cell Activation and Interacts with the LSP-1 Protein in Human Macrophages

  2023cites this paper
• The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma

  2023cites this paper
• Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia

  2023cites this paper
• Upregulated HAVCR2: A Prognostic and Immune-Related Marker in Testicular Germ Cell Tumors

  2023cites this paper
• Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

  2023cites this paper
• Regulatory T cells in lung disease and transplantation

  2023cites this paper
• The relationship between serum TIM-3 and TIM-3 gene expression in a sample of Iraqi patients with multiple sclerosis

  2023cites this paper
• Serpine1 negatively regulates Th1 cell responses in experimental autoimmune encephalomyelitis

  2023cites this paper
• Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target

  2023cites this paper
• TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

  2023cites this paper
• Association of TIM-3 with anterior uveitis and associated systemic immune diseases: a Mendelian randomization analysis

  2023cites this paper
• Functions of LncRNAs, exosomes derived MSCs and immune regulatory molecules in preeclampsia disease.

  2023cites this paper
• Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

  2023cites this paper
• Diagnostic value of peripheral TiM-3, NT proBNP, and Sestrin2 testing in left-to-right shunt congenital heart disease with heart failure

  2023cites this paper
• T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases.

  2023cites this paper
• Single-cell analysis reveals diversity of tumor-associated macrophages and their interactions with T lymphocytes in glioblastoma

  2023cites this paper
• A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling

  2022cites this paper
• Basics of immunooncology and immunotherapy in oncology

  2022cites this paper
• Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion

  2022cites this paper
• eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma

  2022cites this paper
• Blockage of Galectin-Receptor Interactions Attenuates Mouse Hepatic Pathology Induced by Toxoplasma gondii Infection

  2022cites this paper
• Tim3scFv-Transforming Lactobacillus Inhibits Transplanted Tumor of Renal-Cell Carcinoma

  2022cites this paper
• Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

  2022cites this paper
• Tim-3/Galectin-9 signaling pathway is involved in the cytokine changes in mice with alveolar echinococcosis

  2022cites this paper
• Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

  2022cites this paper
• Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets

  2022cites this paper
• The prospect of targeting T cell immunoglobulin and mucin‐domain containing‐3 in renal cell carcinoma immunotherapy

  2022cites this paper
• Tim-3 Blockade Decreases the Apoptosis of CD8+ T Cells and Reduces the Severity of Sepsis in Mice.

  2022cites this paper
• An optimal portfolio of photothermal combined immunotherapy

  2022cites this paper
• Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

  2022cites this paper
• Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases *

  2022cites this paper
• Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.

  2022cites this paper
• Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

  2022cites this paper
• Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma

  2022cites this paper
• New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors

  2022cites this paper
• Regulation of activated T cell survival in rheumatic autoimmune diseases

  2022cites this paper
• Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

  2022cites this paper
• Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

  2022cites this paper